Jason Wittes

Stock Analyst at Roth Capital

(2.76)
# 1,802
Out of 5,139 analysts
60
Total ratings
50.94%
Success rate
5.76%
Average return

Stocks Rated by Jason Wittes

ARS Pharmaceuticals
Sep 4, 2025
Initiates: Buy
Price Target: $40
Current: $10.63
Upside: +276.29%
Stryker
May 2, 2025
Maintains: Buy
Price Target: $405$456
Current: $363.78
Upside: +25.35%
Allurion Technologies
Mar 21, 2025
Reiterates: Buy
Price Target: $16
Current: $1.85
Upside: +764.86%
Fortress Biotech
Mar 11, 2025
Reiterates: Buy
Price Target: $15$16
Current: $3.72
Upside: +330.11%
Orthofix Medical
Feb 26, 2025
Reiterates: Buy
Price Target: $22
Current: $14.08
Upside: +56.25%
IRADIMED CORPORATION
Feb 14, 2025
Reiterates: Buy
Price Target: $60$72
Current: $102.00
Upside: -29.41%
TriSalus Life Sciences
Jan 24, 2025
Reiterates: Buy
Price Target: $11
Current: $5.53
Upside: +99.10%
Globus Medical
Dec 17, 2024
Maintains: Buy
Price Target: $100$115
Current: $93.47
Upside: +23.03%
Journey Medical
Jun 28, 2024
Reinstates: Buy
Price Target: $11
Current: $8.01
Upside: +37.33%
Cardiol Therapeutics
Jun 26, 2024
Initiates: Buy
Price Target: $10
Current: $1.06
Upside: +843.40%
Reinstates: Buy
Price Target: $100
Current: $88.24
Upside: +13.33%
Reiterates: Buy
Price Target: $5
Current: $2.68
Upside: +86.57%
Initiates: Buy
Price Target: $9
Current: $0.84
Upside: +973.60%
Initiates: Buy
Price Target: $75
Current: $23.97
Upside: +212.89%
Initiates: Buy
Price Target: $22
Current: $17.74
Upside: +24.01%
Initiates: Neutral
Price Target: $120
Current: $87.31
Upside: +37.44%
Initiates: Buy
Price Target: $206
Current: $142.06
Upside: +45.01%
Reinstates: Buy
Price Target: $145
Current: $214.62
Upside: -32.44%
Initiates: Buy
Price Target: $15
Current: $23.18
Upside: -35.29%
Initiates: Buy
Price Target: $200
Current: $13.64
Upside: +1,366.28%
Initiates: Buy
Price Target: $26
Current: $30.57
Upside: -14.95%